This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?
by Zacks Equity Research
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024
by Zacks Equity Research
RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
by Kinjel Shah
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
by Zacks Equity Research
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
by Zacks Equity Research
Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
by Zacks Equity Research
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
by Sundeep Ganoria
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
Lilly Loses Around $14B This Week: How to Play LLY Stock
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR
by Zacks Equity Research
Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
by Sanghamitra Saha
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU
by Zacks Equity Research
BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List
by Zacks Equity Research
The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
by Zacks Equity Research
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Zacks Value Trader Highlights: Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy
by Zacks Equity Research
Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy are part of the Zacks Value Trader article.
Stocks Beating the S&P 500 in 2024 (Excluding NVIDIA)
by Tracey Ryniec
Some say it is "easy" to beat the S&P 500 this year. Tracey picked 5 random hot stocks to test the theory.
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
by Zacks Equity Research
Eli Lilly (LLY) reachead $910.69 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
by Zacks Equity Research
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWB